CORDIS
EU research results

CORDIS

English EN
Design and development of advanced NAnomedicines to overcome Biological BArriers and to treat severe diseases

Design and development of advanced NAnomedicines to overcome Biological BArriers and to treat severe diseases

Objective

Many therapeutic targets are shielded behind biological barriers, limiting the possibility to reach them with conventional drugs or diagnostic probes. Biological barriers are even more problematic for most biological pharmaceutics, such as recombinant proteins, antibodies and gene therapeutics. The most promising solution to this challenge is the use of nano-vehicles for specific targeting and delivery. The aim of NABBA is to form European early stage researchers (ESR) with cutting-edge scientific knowledge in the field of nanoparticles (NP) for biomedical application, able to cross biological barriers. For this aim the project will train ESRs, focusing on key aspects of nanobiotechnology: (i) design and chemical synthesis of different types of NPs, (ii) related techniques of detection and characterization, (iii) strategies of loading, targeting and delivery of drugs or diagnostic probes; (iv) proof of principle of pharmacological activity including pharmacokinetics and biodistribution. As a peculiar feature of NABBA, strong emphasis will be devoted to molecular mechanisms ruling biological barriers under physiological and pathological conditions, in order to develop novel nano-technological expedients for their crossing. Strong emphasis will be devoted to advanced chemistry issues, enabling new synthetic strategies either for NP assembly or functionalization. Different biological barriers will be addressed. ESRs will strongly benefit from a network of internationally recognized scientists in the field of chemistry, nanobiotechnology and nanomedicine, and the participation of companies with relevant interests and expertises in the field. The planned cooperation programs between Academia and Industries will allow the circulation of ESRs and this will give them the opportunity for to get acquainted with the most advanced research in the field, the most sophisticated technologies and the most advanced Industrial manufacturing platforms and innovative strategies.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

Address

Piazza Dell'Ateneo Nuovo 1
20126 Milano

Italy

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 917 551,36

Participants (5)

Sort alphabetically

Sort by EU Contribution

Expand all

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE CNRS

France

EU Contribution

€ 525 751,20

UNIVERSITEIT UTRECHT

Netherlands

EU Contribution

€ 255 374,28

UNIVERSIDAD DE SANTIAGO DE COMPOSTELA

Spain

EU Contribution

€ 495 745,92

HELMHOLTZ-ZENTRUM FUR INFEKTIONSFORSCHUNG GMBH

Germany

EU Contribution

€ 498 432,96

ENVIROINVEST KORNYEZETVEDELMI ES BIOTECHNOLOGIAI ZARTKORUEN MUKODO RESZVENYTARASASAG

Hungary

EU Contribution

€ 158 418,82

Partners (4)

Sort alphabetically

Expand all

EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH

SYLENTIS SAU

BIOTALENTUM TUDASFEJLESZTO KFT

NOVARTIS PHARMA AG

Project information

Grant agreement ID: 642028

Status

Closed project

  • Start date

    1 January 2015

  • End date

    28 February 2019

Funded under:

H2020-EU.1.3.1.

  • Overall budget:

    € 2 851 274,54

  • EU contribution

    € 2 851 274,54

Coordinated by:

UNIVERSITA' DEGLI STUDI DI MILANO-BICOCCA

Italy